ライフサイエンスコーパス: abdominal pain

1 R 11.79 [4.30-37.98], p<0.0001 for recurrent abdominal pain).

2 e than a month started complaining of severe abdominal pain.

3 ea is a common symptom in youth with chronic abdominal pain.

4 h CP present with recurrent or chronic upper abdominal pain.

5 or diagnosing ACNES in patients with chronic abdominal pain.

6 re gastrointestinal bleeding and episodes of abdominal pain.

7 ly included bowel obstruction, bleeding, and abdominal pain.

8 experienced erythema, wheezing, nausea, and abdominal pain.

9 pneumonia developed with generalized, acute abdominal pain.

10 pinal G-CSF as a target for treating chronic abdominal pain.

11 or the physician's in the screening of acute abdominal pain.

12 most common presentation in the Px group was abdominal pain.

13 These processes might link stress with abdominal pain.

14 of KOR agonists for the treatment of chronic abdominal pain.

15 n who presented with a sudden - onset severe abdominal pain.

16 cument acute appendicitis or other causes of abdominal pain.

17 disease generally represented by right lower abdominal pain.

18 dely associated with symptoms of fatigue and abdominal pain.

19 ry from asymptomatic abdominal mass to acute abdominal pain.

20 ented to our emergency department with acute abdominal pain.

21 domen was performed to evaluate the cause of abdominal pain.

22 year-old postmenopausal woman presented with abdominal pain.

23 ith the most common presenting symptom being abdominal pain.

24 e most common side effects were vomiting and abdominal pain.

25 ecause it can rule out other causes of acute abdominal pain.

26 itted to the emergency department with acute abdominal pain.

27 gesics, and one in five suffered from severe abdominal pain.

28 ent episodes of carpopedal spasms and crampy abdominal pains.

29 symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 million (95% CI, 0.8-1.2) visits for

30 ion), biliary tract disease ($10.3 billion), abdominal pain ($10.2 billion), and inflammatory bowel d

31 mon serious adverse event in both groups was abdominal pain (11 [4%] in the imatinib group, 14 [4%] i

32 aminotransferase concentration (12; 4%), and abdominal pain (11; 3%).

33 ophosphataemia (19 [6%]), anaemia (17 [5%]), abdominal pain (13; 4%), and elevated lipase level (15;

34 During follow-up, 70 of 450 patients with abdominal pain (15%), 53 of 387 with chest pain and/or d

35 ]), depression (124 [17%] of 713 responses), abdominal pain (178 [22%]), and ocular disorders (142 [1

36 ausea/vomiting 7.8% (95% CI, 7.1%-8.5%), and abdominal pain 2.7% (95% CI, 2.0%-3.4%).

37 [13%] of 156 patients in the placebo group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea (16 [10%

38 ; one [1%] grade >=3), diarrhoea (23 [32%]), abdominal pain (20 [27%]; two [3%] grade >=3), decreased

39 ents with monogenic Crohn's disease, 35% had abdominal pain, 24% had nonbloody loose stool, 18% had v

40 ecisions changed in 116 of 457 patients with abdominal pain (25%), 72 of 387 with chest pain and/or d

41 uropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]).

42 symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), and diarrhea (30/58 [52%])

43 clinical adverse events were fatigue (55%), abdominal pain (34%), and nausea (19%).

44 health care contact after RYGB surgery were abdominal pain (489 [34.2%]), fatigue (488 [34.1%]), and

45 , constipation (7.4% and 8.6% vs. 2.5%), and abdominal pain (5.8% and 7.2% vs. 4.1%).

46 The percentage of responders for abdominal pain (50.6% vs 42.2%; P = .018) was significan

47 iagnosis changed in 235 of 460 patients with abdominal pain (51%), 163 of 387 with chest pain and/or

48 Adults were more likely to present with abdominal pain (71.8% vs 40.7%; P < .001) and children w

49 oms in CD were tiredness/fatigue (80.6%) and abdominal pain (80.4%) while passage of blood with bowel

50 complications [PEF 28 (25.2%), NV 4 (3.6%), abdominal pain 9 (8.1%), infection 7 (6.3 %), AHD 13 (11

51 RCP pancreatitis (PEP), defined by new upper-abdominal pain, a lipase level more than 3-fold the uppe

52 , use of pain modulators, moderate to severe abdominal pain, a severe gastroesophageal reflex, and mo

53 nflammation of the urinary or genital tract, abdominal pain, abdominal mass, obstructive uropathy, in

54 evening) for the past 10 days and left flank abdominal pain, accompanied by sweating and fatigue.

55 s characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas,

56 as with clinical manifestations ranging from abdominal pain, acute pancreatitis, exocrine and/or endo

57 Risk of persisting need for insulin or abdominal pain after having had two versus one asparagin

58 Consecutive patients admitted for abdominal pain after RYGB and undergoing CT and surgical

59 ys be remembered in patients presenting with abdominal pain after stent insertion.

60 thms and the WHO vaginal discharge and lower abdominal pain algorithms with gold standard testing.

61 y presented to our emergency department with abdominal pain alongside elevated inflammatory markers a

62 inal bleeding accompanied by the episodes of abdominal pain - an ectopic pancreas located in the ileu

63 ing three cases was iron deficiency anaemia, abdominal pain and acute intestinal obstruction, respect

64 The trial included adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loo

65 n presented to the emergency department with abdominal pain and bloody diarrhoea.

66 mmunosuppressed patients with fever, chills, abdominal pain and cholestasis with progressive jaundice

67 We measured improvement in worst abdominal pain and composite pain score using the Pain F

68 We studied 11 patients with abdominal pain and diarrhea caused by early-onset protei

69 ur center with the chief complaint of severe abdominal pain and diarrhea for 2 years that had worsene

70 s associated with gastrointestinal symptoms (abdominal pain and diarrhea) and musculoskeletal symptom

71 a multitude of symptoms, including vomiting, abdominal pain and diarrhea.

72 BD) tend to avoid dairy products to minimize abdominal pain and diarrhea.

73 should be considered in a patient with upper abdominal pain and elevated amylase in the context of an

74 Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed by a self-a

75 One day following discharge from hospital abdominal pain and frequent non-bloody diarrhea recurred

76 We included 401 patients with abdominal pain and gallstones (assumed eligible for chol

77 Patients >=18 years with abdominal pain and gallstones were included at five surg

78 low pandisaccharidase may be correlated with abdominal pain and have a unique frequency of GI symptom

79 epartment with complaints of breathlessness, abdominal pain and hematuria for the last 6 months.

80 who presented with 1 week history of diffuse abdominal pain and high grade fever, associated with vom

81 who had a composite response of decrease in abdominal pain and improvement in stool consistency on t

82 She presented with abdominal pain and inflammatory syndrome revealing a col

83 hronic pancreatitis often results in chronic abdominal pain and is most commonly caused by excessive

84 8-year-old female patient with complaints of abdominal pain and jaundice.

85 several gastrointestinal conditions, such as abdominal pain and motility-related disorders.

86 In an oral food challenge test, she felt abdominal pain and nausea only after eating fruit, along

87 The patient complained of cramp-like abdominal pain and nausea.

88 at may be marked by debilitating symptoms of abdominal pain and obstruction.

89 patient presented with complaints of severe abdominal pain and palpable pulsatile abdominal mass loc

90 -D and IBS-M, respectively, with decrease of abdominal pain and resolution of "diarrhea".

91 ove other gastrointestinal symptoms, such as abdominal pain and satiety.

92 to 18 years) with unclear chronic/recurrent abdominal pain and suspected FM/LM.

93 plication observed was nonspecific transient abdominal pain and transient hypotension.

94 However, the patient began to experience abdominal pain and vomiting after ingestion of egg appro

95 ncy Department with complaints of epigastric abdominal pain and vomiting.

96 ith jejunal diverticulitis accompanying with abdominal pain and vomiting.

97 symptoms of obstructive jaundice, including abdominal pain and yellowing of the skin.

98 r body areas, endometriosis can cause severe abdominal pain and/or infertility.

99 d female presented with diarrhoea, vomiting, abdominal pain, and bloating.

100 nt with the classic symptoms of weight loss, abdominal pain, and bloody diarrhea, many present with n

101 with trichinellosis, characterized by fever, abdominal pain, and diarrhea, along with eosinophilia ra

102 mon adverse events included nasopharyngitis, abdominal pain, and diarrhea.

103 Demographic characteristics, risk factors, abdominal pain, and disease burden.

104 al abdominal discomfort, abdominal bloating, abdominal pain, and flatulence on a scale of 1-6.

105 g self-limiting conditions including nausea, abdominal pain, and FMT-related diarrhea.

106 ons in pancreatic enzymes, re-admissions for abdominal pain, and incidentalomas.

107 included fever duration, diarrhea, vomiting, abdominal pain, and leukocytopenia.

108 Adverse events included mild diarrhea, abdominal pain, and nausea.

109 the study period, 288 (8.5%) presented with abdominal pain, and of these 199 (69%) patients were enr

110 Hemorrhage, abdominal pain, and perforation were the most common cau

111 ptom scores (fullness, distention, bloating, abdominal pain, and sickness) in CD participants compare

112 rent fever, fatigue, elevated liver enzymes, abdominal pain, and significant weight loss.

113 luding colonic (ie, perforation, hemorrhage, abdominal pain), anesthesia-associated (ie, pneumonia, i

114 conditions in patients with IBD are chronic abdominal pain, anxiety, and depression.

115 tal bleeding [RB], stool frequency [SF]; CD: abdominal pain [AP], liquid stools [LS]) and outcome dur

116 ms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme abnormalities, h

117 revalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormal

118 ointestinal disorder with symptoms including abdominal pain associated with a change in stool form or

119 e paradoxical development of or increases in abdominal pain associated with continuous or increasing

120 contributes to visceral hypersensitivity and abdominal pain associated with many gastrointestinal dis

121 For failure to achieve improvement in abdominal pain at 4-12 weeks, tricyclic antidepressants

122 ars of age and younger presenting with acute abdominal pain at a tertiary care institution from Janua

123 HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due

124 after a single 250 mg dose (one subject) and abdominal pain, back pain, and eczema after multiple dos

125 y, no differences were found for severity of abdominal pain, bloating and flatulence, and QoL score b

126 ic emptying and vomiting, as well as nausea, abdominal pain, bloating, and early satiety compared wit

127 ble bowel syndrome (IBS) is characterized by abdominal pain, bloating, and erratic bowel habits.

128 ylobacter infection [grade 3]; recurrence of abdominal pain, bloating, diarrhoea, and urinary tract i

129 Secondary end points included nausea, abdominal pain, bloating, early satiety, as well as the

130 the severity of 5 gastrointestinal symptoms (abdominal pain, bloating, nausea, gas, and fullness) bef

131 ldren (known as MIS-C), manifested by severe abdominal pain, cardiac dysfunction and shock.

132 oenterology outpatient department with acute abdominal pain centered in the epigastrium.

133 0%, and 13%, respectively, for patients with abdominal pain, chest pain and/or dyspnea, and headache;

134 ncy department who were referred for CT with abdominal pain, chest pain and/or dyspnea, or headache w

135 scenario is a young patient presenting with abdominal pain, chronic diarrhoea, weight loss, and fati

136 the 8 mg/kg dose of ramucirumab had grade 3 abdominal pain, colitis, hepatitis, interstitial lung di

137 ecrease in the weekly average of worst daily abdominal pain compared with baseline in at least 4 week

138 stical correlation between lead toxicity and abdominal pain consistency and intensity, constipation,

139 c diseases with signs and symptoms including abdominal pain, constipation, diarrhea, nausea, vomiting

140 taking add-on antidepressants suffered from abdominal pain, constipation, dizziness, and dry mouth.

141 ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure, and early

142 irritable bowel syndrome, chronic functional abdominal pain, constipation, or diarrhea.

143 Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most comm

144 ) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing.

145 estinal disorder characterized by persistent abdominal pain despite recovery from acute gastroenterit

146 uded, presented to emergency room with acute abdominal pain diagnosed as primary fat necrosis.

147 ally observed in patients with IBD including abdominal pain, diarrhea, and poor growth.

148 disease (EVD) symptoms (eg, fever, headache, abdominal pain, diarrhea, emesis, and fatigue) with symp

149 symptoms were grouped into four categories, abdominal pain, diarrhea, weight loss, and gastroesophag

150 n presented to his local hospital with acute abdominal pain, diarrhoea, and vomiting, and was admitte

151 rmint oil did, however, significantly reduce abdominal pain, discomfort, and IBS severity.

152 Secondary endpoints included abdominal pain, discomfort, symptom severity, and advers

153 nked to SIBO include bloating, diarrhea, and abdominal pain/discomfort.

154 rs" (AP-FGID) has been changed to functional abdominal pain disorders (FAPD) and we have derived a ne

155 e interventions for children with functional abdominal pain disorders (FAPDs).

156 Functional abdominal pain disorders are common disorders with a pre

157 Paediatric functional abdominal pain disorders, currently referred to as disor

158 Therefore, patients present with cyclical abdominal pain during menstruation along with normal men

159 11, para 8) presented with increasing severe abdominal pain during the first trimester of pregnancy a

160 GS subjects and jaundice was associated with abdominal pain, dyspepsia or loss of appetite in 54 (53.

161 57 patients, most commonly hypokalaemia and abdominal pain (each three [5%] patients).

162 Average duration of abdominal pain episodes correlated with GE (r = -0.58, p

163 fferential of patients complaining of sudden abdominal pain, especially after chronic PEG utilization

164 food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnut

165 sented with a variety of symptoms, including abdominal pain, fatigue, muscle weakness, and low plasma

166 old woman presented with a 1-week history of abdominal pain, fever and jaundice.

167 sian boy presented with a two-day history of abdominal pain, fever up to 40 degrees C, and polyuria.

168 ommon AEs reported were headache, dizziness, abdominal pain, fever, nausea, and fatigue.

169 common drug-related adverse events included abdominal pain (five [10%] of the 48 participants while

170 hy (five [28%]), diarrhoea (five [28%]), and abdominal pain (four [22%]).

171 n Dar Es Salaam, Tanzania with non-traumatic abdominal pain from September 2017 to October 2017.

172 l abuse presented to the hospital with acute abdominal pain, generalized weakness, weight loss, and p

173 Scores obtained for severity of abdominal pain had a negative correlation with A (r = -0

174 tection of salivary VZV DNA in patients with abdominal pain helps to identify putative enteric zoster

175 y care providers (PCPs) for CT evaluation of abdominal pain, hematuria, or weight loss were identifie

176 In patients with abdominal pain, hematuria, or weight loss, leading diagn

177 y using a composite of four variables: worst abdominal pain, IBS symptom frequency, Bristol Stool For

178 Abdominal pain in adults represents a wide range of illn

179 nce, presentation, causes and mortality from abdominal pain in an established emergency department of

180 estinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel mo

181 fferential diagnosis of severe and resistant abdominal pain in patients referring to general EDs or G

182 s study aimed to determine the prevalence of abdominal pain in patients seen in the Laghman Hakim Hos

183 reatment-related serious adverse events were abdominal pain in patients with gastric or gastro-oesoph

184 preventing glycation reactions might reduce abdominal pain in patients with IBS with sensitivity to

185 ced visceral hypersensitivity, symptoms, and abdominal pain in patients with IBS.

186 DNF) has been reported to be associated with abdominal pain in patients with irritable bowel syndrome

187 Chronic abdominal pain in some patients is caused by the anterio

188 bowel syndrome is characterised by worsening abdominal pain in the context of escalating or continuou

189 nal infections, gastrointestinal disease, or abdominal pain in the first year of life.

190 ttent melena, accompanied by the episodes of abdominal pain in the left upper quadrant and generalize

191 He had experienced similar episodes of abdominal pain in the past that had been treated with su

192 a for Adverse Events, version 4.03) included abdominal pain (in 18% of patients), nausea (8%), ascite

193 se events were nausea (in ten participants), abdominal pain (in six), and vomiting (in five).

194 is is exemplified in the assessment of acute abdominal pain, in which a physician's palpation determi

195 ation fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation

196 ints were: 1) a decrease of more than 50% in abdominal pain intensity and frequency scores; and 2) fo

197 Abdominal pain is a frequent postoperative complication

198 Differential diagnosis can be difficult as abdominal pain is common in pediatric C1-INH-HAE, but al

199 fter Roux-en-Y gastric bypass (RYGB) chronic abdominal pain is common, however the etiology is largel

200 regarding patients with unexplained chronic abdominal pain is sparse.

201 ns (ie, increased frequency of loose stools, abdominal pain), it is hard to differentiate C. difficil

202 She consulted for a 6-months oppressive abdominal pain located in the mesogastrium as well as ab

203 change in bowel habit, hoarseness, fatigue, abdominal pain, lower abdominal pain, weight loss, and t

204 Abdominal pain may be a presenting symptom of lead poiso

205 an score after FMT, 0.37; range, 0.00-1.00), abdominal pain (mean reduction, 26%; median score before

206 dominal pain were defined as those reporting abdominal pain more than 2 times weekly within the last

207 th of FMT included diarrhea (n = 5 [2%]) and abdominal pain (n = 4 [2%]); 3 patients (1%) had hospita

208 ts have had an appendectomy due to recurrent abdominal pain (n = 5) or parental wish (n = 1) during t

209 n = 129 [77.7%]), fatigue (n = 116 [69.8%]), abdominal pain (n = 90 [54.2%]), headache (n = 87 [52.4%

210 fibrillation (n=2 [4%]), sepsis (n=2 [4%]), abdominal pain (n=1 [2%]), syncope (n=1 [2%]), celluliti

211 n=2), anaemia (n=1), pneumothorax (n=1), and abdominal pain (n=1, unlikely related).

212 necrosis and persistent unwellness marked by abdominal pain, nausea, vomiting, and nutritional failur

213 urnal dyspnea, swelling of the legs or feet, abdominal pain, nausea, vomiting, melena, or hematochezi

214 eight [15%] patients vs ten [16%] patients), abdominal pain (nine [17%] patients vs four [6%] patient

215 For failure to achieve an improvement in abdominal pain, none of the active treatments showed sup

216 with incidence rate ratios close to 1.0 for abdominal pain, nonspecific pain, headache, hypotension/

217 dyspepsia, abdominal migraine and functional abdominal pain not otherwise specified, as defined by th

218 and we have derived a new term, "functional abdominal pain -not otherwise specified", to describe ch

219 wo serious adverse events (biliary colic and abdominal pain), occurring in the same participant, were

220 t repeat treatment, defined as a decrease in abdominal pain of >/=30% from baseline and a decrease in

221 ocedures were symptomatic cholelithiasis and abdominal pain of unknown origin.

222 mbocytopenia (seven [7%] vs three [6%]), and abdominal pain (one [1%] vs three [6%]).

223 vent: autoimmune disorder (two [13%]), lower abdominal pain (one [7%]), fatigue (one [7%]), and influ

224 c of Loghman Hakim Hospital with unexplained abdominal pain or abdominal pain resistant to treatment

225 tients still needed insulin or had recurrent abdominal pain or both.

226 was not recommended in patients with chronic abdominal pain or diarrhea, in whom there was no evidenc

227 based on Rome III criteria, with symptoms of abdominal pain or discomfort for at least 2 days/wk) and

228 rritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FA

229 severe asparaginase-associated pancreatitis (abdominal pain or pancreatic enzymes at least three time

230 95% CI, 1.59-3.23) and severe self-reported abdominal pain (OR 2.82, 95% CI 1.64-4.84).

231 association between low lactase activity and abdominal pain (OR = 1.78; 95% CI = 1.07-2.97; p < 0.05)

232 ratio < 0.2 were found to be associated with abdominal pain (OR = 2.25; 95% CI = 1.25-4.04; p < 0.05)

233 ), hemorrhage (OR, 1.28; 95% CI, 1.27-1.30), abdominal pain (OR, 1.07; 95% CI, 1.05-1.08), complicati

234 ong analgesics was a risk factor for chronic abdominal pain (OR, 2.26; 95% CI, 1.59-3.23) and severe

235 ating (P < .04), and of depression levels on abdominal pain (P = .007), reflecting a general upward s

236 ements than placebo in secondary outcomes of abdominal pain (P = .016), discomfort (P = .020), and IB

237 afety for total number of adverse events and abdominal pain (P-score 0.08).

238 atitis was defined by at least two criteria: abdominal pain, pancreatic enzymes at least three times

239 reporting bloody diarrhea, fever, vomiting, abdominal pain; percentage hospitalized; duration of hos

240 , algorithms for vaginal discharge and lower abdominal pain perform poorly in women.

241 ts post-cholecystectomy, whereas non-biliary abdominal pain persists in >40%, particularly in those w

242 miting frequency and symptom scores (nausea, abdominal pain, postprandial fullness, and bloating) on

243 n presented to the emergency department with abdominal pain preceded by approximately one month of fr

244 ns of leukocytes), feasibility (evaluated by abdominal pain recurrence), the presence and recurrence

245 The presence of abdominal pain reduced the risk (OR 0.5 (0.3-0.7)), whil

246 Rome III "abdominal pain related functional gastrointestinal disor

247 S with Neuro-Stim has sustained efficacy for abdominal pain-related functional gastrointestinal disor

248 ed the efficacy of PENFS in adolescents with abdominal pain-related functional gastrointestinal disor

249 d 11-18 years) who met Rome III criteria for abdominal pain-related functional gastrointestinal disor

250 safe and effective therapies for paediatric abdominal pain-related functional gastrointestinal disor

251 8, 2015, and Nov 17, 2016, 115 children with abdominal pain-related functional gastrointestinal disor

252 ood counts, but with headaches, lethargy, or abdominal pain, reported symptom resolution with prophyl

253 ts undergoing RYGB surgery developed chronic abdominal pain requiring strong analgesics, and one in f

254 Hospital with unexplained abdominal pain or abdominal pain resistant to treatment were enrolled.

255 Abdominal pain response did not differ significantly bet

256 uced statistically significant reductions in abdominal pain response or overall symptom relief, when

257 The primary endpoint was abdominal pain response, as defined by the US Food and D

258 eduction from baseline of the weekly average abdominal pain score for 6 or more of 12 weeks of treatm

259 e 46% vs placebo 13%; P = .024), and reduced abdominal pain scores (ebastine 39 +/- 23 vs placebo 62

260 The primary efficacy endpoint was change in abdominal pain scores.

261 is (eight [5%]), hyponatraemia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]).

262 rious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), chola

263 M is a rare anomaly that presents with upper abdominal pain, signs of acute pancreatitis and massive

264 rl who presented with dysmenorrhea and lower abdominal pain since a few months.

265 10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conj

266 ome, IBS, bloating, constipation, functional abdominal pain, sphincter of Oddi dyskinesia, pelvic flo

267 symptoms and higher frequencies of vomiting, abdominal pain, swollen stomach, and loss of appetite, c

268 Abdominal pain, symptom relief, and health-related quali

269 Centrally Mediated Abdominal Pain Syndrome (CAPS), formerly known as Functi

270 and functional abdominal pain or functional abdominal pain syndrome (FAP[S]).

271 yndrome (CAPS), formerly known as Functional Abdominal Pain Syndrome, can be distinguished from other

272 old male was admitted due to recurring upper abdominal pain that lasted several weeks.

273 e individuals within a population defined by abdominal pain that might have enteric zoster.

274 cy department with subacute poorly localized abdominal pain that was increasing in intensity.

275 frame, developing a severe (NRS 6-8) chronic abdominal pain that was only diagnosed after a substanti

276 ib group were anaemia (seven [4%] patients), abdominal pain (three [2%] patients), and intestinal obs

277 Symptoms may range from mild abdominal pain to life-threatening obstruction and stran

278 of chronic constipation presents with severe abdominal pain to the emergency department.

279 ediate allergic reaction including erythema, abdominal pain, vomiting, and anaphylactic shock.

280 ore with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain.

281 The prevalence of postoperative chronic abdominal pain was 11% and the prevalence of severe self

282 % and the prevalence of severe self-reported abdominal pain was 21%.

283 Pancreatitis-related abdominal pain was a major symptom in 81% of children wi

284 Abdominal pain was associated with significant morbidity

285 istory of hysterectomy presenting with vague abdominal pain was completely evaluated with ultrasound

286 ere similar between the two groups, although abdominal pain was more common in adults, and weight los

287 ressants were ranked first for efficacy when abdominal pain was used as the outcome measure.

288 , hoarseness, fatigue, abdominal pain, lower abdominal pain, weight loss, and the "any other symptom"

289 sting need for insulin therapy and recurrent abdominal pain were associated with having had pseudocys

290 Patients with severe self-reported abdominal pain were defined as those reporting abdominal

291 Patients with chronic abdominal pain were defined as those using strong analge

292 Adult patients with gallstones and abdominal pain were included.

293 ation in immunocompetent, while diarrhea and abdominal pain were more common in immunocompromised.

294 greater symptoms of reflux, indigestion and abdominal pain were reported.

295 Icterus, fever, and abdominal pain were the leading symptoms.

296 ent in global IBS symptoms or improvement in abdominal pain, were included.

297 on presenting symptoms in CD are fatigue and abdominal pain while in UC bloody BM and diarrhea are mo

298 One hundred seventeen patients with acute abdominal pain who underwent abdominal CT were enrolled

299 syndrome generally present with nonspecific abdominal pain, with the left renal vein (LRV) lodged be

300 rior to the current admission, she developed abdominal pain, worsening diarrhea and was diagnosed wit